Abstract 32P
Background
Hypoxia is characterized by low oxygen levels in tissues and plays a significant role in the development and progression of gliomas. Hypoxia induces activation of several signals including STAT3 which has been implicated in the cancer progression and development of drug resistance including in gliomas used temozolomide (TMZ) via modulation of O6-methylguanin-DNA-methyltransferase (MGMT) mediated repair of TMZ-induced DNA damage.
Methods
Our study was focused on the expression of STAT3 and hypoxia related factors in a set of repeatedly resected glioma patients (one patient without treatment, seven patients with chemoradiotherapy) and glioma cell lines with normal and knockout STAT3 using IHC, mutational and RT-PCR analyses correlated with clinical data.
Results
In patients' samples, IHC analysis showed that in all but one repeated glioma resections from individual patients pSTAT3 levels were elevated. Higher pSTAT3 levels as well as MGMT methylation status corresponded with a shortened survival of these patients. Further analyses carried out in cryopreserved glioma samples revealed upregulation of STAT3 in an untreated patient corresponding with upregulation of hypoxia factors (HIF1α, HIF1β), proangiogenic factor VEGFA and EGFR. STAT3 knockout in glioma cells produced a similar trend - downregulation of hypoxia and proangiogenic factors.
Conclusions
Our results demonstrated a biological relationship between the expression of pSTAT3, hypoxia and proangiogenic factors and MGMT methylation in both cultivated glioma cells and glioma resected samples. Moreover, we discovered that pSTAT3 levels tend to increase in repeated resections. MGMT methylation status and increased pSTAT3 levels in these samples correlate with shorter survival of investiagted glioma bearing patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Ministry of Health, Czech Republic, project No. NU20-03-00360.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract